This is a preprint.
Genetic elements promote retention of extrachromosomal DNA in cancer cells
- PMID: 41278658
- PMCID: PMC12632332
- DOI: 10.1101/2025.10.10.681495
Genetic elements promote retention of extrachromosomal DNA in cancer cells
Update in
-
Genetic elements promote retention of extrachromosomal DNA in cancer cells.Nature. 2026 Jan;649(8095):152-160. doi: 10.1038/s41586-025-09764-8. Epub 2025 Nov 19. Nature. 2026. PMID: 41261124 Free PMC article.
Abstract
Extrachromosomal DNA (ecDNA) is a prevalent and devastating form of oncogene amplification in cancer1,2. Circular megabase-sized ecDNAs lack centromeres and segregate stochastically during cell division3-6 yet persist over many generations. EcDNAs were first observed to hitchhike on mitotic chromosomes into daughter cell nuclei over 40 years ago with unknown mechanism3,7. Here we identify a family of human genomic elements, termed retention elements, that tether episomes to mitotic chromosomes to increase ecDNA transmission to daughter cells. We develop Retain-seq, a genome-scale assay that reveals thousands of human retention elements conferring generational persistence to heterologous episomes. Retention elements comprise a select set of CpG-rich gene promoters and act additively. Live-cell imaging and chromatin conformation capture show that retention elements physically interact with mitotic chromosomes at regions which are mitotically bookmarked by transcription factors and chromatin proteins, intermolecularly recapitulating promoter-enhancer interactions. Multiple retention elements are co-amplified with oncogenes on individual ecDNAs in human cancers and shape their sizes and structures. CpG-rich retention elements are focally hypomethylated; targeted cytosine methylation abrogates retention activity and leads to ecDNA loss, suggesting that methylation-sensitive interactions modulate episomal DNA retention. These results highlight the DNA elements and regulatory logic of mitotic ecDNA retention. Amplifications of retention elements promote the maintenance of oncogenic ecDNA across generations of cancer cells, revealing the principles of episome immortality intrinsic to the human genome.
Conflict of interest statement
Competing Interests H.Y.C. is an employee and stockholder of Amgen as of Dec. 16, 2024. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Biosciences, Orbital Therapeutics, and was an advisor of Arsenal Biosciences, Chroma Medicine, Exai Bio and Vida Ventures until Dec. 15, 2024. P.S.M. is a co-founder and advisor of Boundless Bio. A.G.H. is a founder and shareholder of Econic Biosciences. M.G.J. is a consultant for and holds equity in Vevo Therapeutics. The remaining authors declare no competing interests.
Figures
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources